Diagnostics

• Skeletal Scintigraphy With 18F Sodium Fluoride Positron Emission Tomography (18F-fluoride PET) Offers Greater Overall Accuracy Than 99mTechnetium-MDP for Prostate Cancer Patients (May 2008)

• PSA "Bounce" Following Permanent Seed Brachytherapy - A Challenge To Identify And A Cause Of Anxiety For Patients. (January 2008)

• Partin Tables Updated (January 2008)

• "Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients with High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies" - JCO August 1, 2007 (January 2008)

• Gleason Score Upgrading From Biopsy To Prostatectomy Specimen (January 2008)

• EPCA-2: A Highly Specific Serum Marker for Prostate Cancer (May 2007)

• PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy (May 2007)

• Evaluation of Prostascint Scan (May 2007)

• "Molecular Staging" Assessing The E-Cadherin Gene: When The Loss Of A Gene Can Have Predictive Potential (November 2006)

• Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride [0.5 mg/d] (October 2006)

• Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition (October 2006)

• National Comprehensive Cancer Network (Nccn) Establishes 2006 Guidelines For Early Detection Of Prostate Cancer (October 2006)

• Modified PSA Guidelines For Bone Scanning (October 2006)

• UPM3 - A diagnostic urine test with greater accuracy for cancer detection than PSA (April 2006)

• Percentage of Positive Biopsy Cores: Riddle - “When is the risk of a Gleason 4 + 3, not that of a “4 + 3”? Answer: When less than 50% of the cores show cancer. (April 2006)

• Lymphoscintigraphy And Radio-Guided Surgery For Sentinel Lymph Node Identification In Low-Risk Clinically Localized Prostate Cancer (January 2006)

• The Importance of Percentage of Gleason Grades 4 Plus 5 in Predicting Biochemical Recurrence in Prostate Cancer (June 2005)

• The Utility of Bone Scans in Recurrent Prostate Cancer (June 2005)

• Early Detection and Treatment Outcome for Aggressive Disease (March 2005)

• A Revisit: Strategy For Re-Biopsy After An Initial Diagnosis Of Isolated HGPIN (January 2005)

• "High Grade Prostatic Intraepithelial Neoplasia Is A Disease" (January 2005)

• The Prostate Specific Antigen Has Become Less Informative Over The Past 20 Years (December 2004)

• Candidates For The Next Generation Of Prostate Cancer Detection Tools (December 2004)

• What's New In Testing For Prostate Cancer?: "Upm3, A New Molecular Urine Test For The Detection Of Prostate Cancer (Oct 2004)

• The Biopsy Gleason Score: Only An Estimate Of The Final Pathological Gleason Score, But The Best Estimate We Can Get (Sept 2004)

• Interpreting The Results Of PSA Testing (March 2004)

• Bone Scan Staging Not Recommended When PSA Is < 20 ng/mL (Jan 2004)

• TheTechnetium-99m Radionuclide Bone Scan (December 2003)

• Post Therapy PSA Doubling Time Of <3 Months Is A Surrogate For  Prostate Cancer Specific Mortality (Nov 2003)

• A Nomogram Integrating Variables Affecting Outcome Of Salvage Radiation Therapy Post-Rp (Nov 2003)
• Is Occult Cancer in Lymph Nodes the Achilles Heal of Successful treatment? A Few Cells May Cast a Long shadow (October 2003)
• Now the World Knows We Need a Better Mousetrap (October 2003)
• Percent Of Biopsy Cores That Are Positive Improves Prediction (September 2003)
• Improved MRI Technique for Detection of Lymph Node Metastases (August 2003)
• Interaction Of Finasteride (Proscar) And Psa: A Potential Problem In Diagnosis (July 2003)
• PAP – Making a Comeback as a Prognostic Indicator (May 2003)
• Complexed PSA discussed in relation to standard PSA test. (December 2002)
• Testing for PC using proteomic patterns. (December 2002)
• Free PSA further refined to assist clearer diagnostic implications. (October 2002)

« Back to topic index